Table II.
µCT analysis of cortical bone in male placebo (vehicle)- and etidronate-treated Enpp1−/− and WT mice.
| WT
|
Enpp1−/−
|
|||
|---|---|---|---|---|
| Placebo | Etidronate | Placebo | Etidronate | |
| Co.BMD (g/cm3) | 1.18±0.018 | 1.18±0.020 | 1.20±0.024 | 1.20±0.011a |
| Co.Po (%) | 53.27±7.26 | 54.79±5.64 | 61.75±3.71a,c | 63.11±4.85a,c |
| Co.Th (µm) | 197.90±1.91 | 195.64±3.84 | 175.98±5.96a,d | 169.86±15.92a,d |
| Co.Area (µm2) | 5.14E+06±5.57E+05 | 5.09E+06±3.72E+05 | 4.47E+06±4.2E+05a,e | 4.17E+06±4.3E+05a,e |
Results are expressed as the means ± SEM.
a
Significant difference compared to wild-type (WT) mice;
b
significant difference compared to placebo-treated mice.
c
P<0.05;
d
P<0.01;
e
P<0.001. µCT, micro-computed tomography; cortical bone mineral density; Co.BMD, cortical bone mineral density; Co.Po; cortical porosity; Co.Th, cortical thickness; Co.Area, cortical area.